<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00695110</url>
  </required_header>
  <id_info>
    <org_study_id>CLAR-08005</org_study_id>
    <nct_id>NCT00695110</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Oral Testosterone (T) Ester Formulations in Hypogonadal Men</brief_title>
  <official_title>Phase II, Repeat Dose, Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clarus Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Los Angeles Biomedical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clarus Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pharmacokinetic study is to determine whether oral testosterone ester
      formulations can be used effectively to treat men with low testosterone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum testosterone Cmax</measure>
    <time_frame>7 day treatment cycles with washouts</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum testosterone Cavg</measure>
    <time_frame>7 day treatment cycles with washouts</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum testosterone Tmax</measure>
    <time_frame>7 day treatment cycles with washouts</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum testosterone AUC</measure>
    <time_frame>7 day treatment cycles with washouts</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum DHT Cmax</measure>
    <time_frame>7 day treatment cycles with washouts</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum DHT Cavg</measure>
    <time_frame>7 day treatment cycles with washouts</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum DHT Tmax</measure>
    <time_frame>7 day treatment cycles with washout</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum DHT AUC</measure>
    <time_frame>7 day treatment cycles with washouts</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean serum estradiol</measure>
    <time_frame>7 day treatment cycles with washout</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Testosterone undecanoate (TU) (300 mg T equivalents) BID for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TU + testosterone enanthate (TE) (400 mg T equivalents) BID for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TU (200 mg T equivalents) BID for 8 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TU + TE (300 mg T equivalents) BID for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone undecanoate (TU)</intervention_name>
    <description>300 mg T equivalents BID for 7 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TU + testosterone enanthate (TE)</intervention_name>
    <description>400 mg T equivalents BID for 7 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone undecanoate (TU)</intervention_name>
    <description>200 mg T equivalents BID for 8 days; pharmacokinetics determined when oral TU administered with and without food.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TU + testosterone enanthate (TE)</intervention_name>
    <description>300 mg T equivalents BID for 7 days</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male, ages 18-68

          -  Serum total testosterone less than or equal to 275 ng/dL

        Exclusion Criteria:

          -  Significant intercurrent disease of any type, in particular, liver, kidney or heart
             disease, uncontrolled diabetes mellitus or psychiatric illness.

          -  Abnormal prostate digital rectal examination, elevated PSA, AUA symptom score of &gt;15,
             and/or history of prostate cancer.

          -  Hematocrit of &lt;35 or &gt;50%

          -  BMI &gt;36

          -  Serum transaminases &gt; 2 times upper limit of normal or serum bilirubin &gt; 2.0 mg/dL
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald S Swerdloff, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Los Angeles Biomedical Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gregory Flippo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alabama Clinical Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven J. Kulback, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alabama Internal Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sherwyn Schwartz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>dgd Research, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Clinical Therapeutics</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alabama Internal Medicine</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>dgd Research, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2008</study_first_submitted>
  <study_first_submitted_qc>June 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2008</study_first_posted>
  <disposition_first_submitted>August 17, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>August 17, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 19, 2010</disposition_first_posted>
  <last_update_submitted>August 23, 2010</last_update_submitted>
  <last_update_submitted_qc>August 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Robert E. Dudley, PhD, President and CEO, Clarus Therapeutics, Inc.</name_title>
    <organization>Clarus Therapeutics, Inc.</organization>
  </responsible_party>
  <keyword>testosterone</keyword>
  <keyword>male hypogonadism</keyword>
  <keyword>low testosterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

